Nykredit A S Makes New Investment in Zoetis Inc. $ZTS

Nykredit A S purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) in the second quarter, HoldingsChannel reports. The institutional investor purchased 139,745 shares of the company’s stock, valued at approximately $10,042,000.

Several other hedge funds and other institutional investors have also modified their holdings of ZTS. J. Stern & Co. LLP increased its position in Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares during the period. Norges Bank acquired a new stake in Zoetis in the 4th quarter worth $734,425,000. Flossbach Von Storch SE acquired a new stake in Zoetis in the 2nd quarter worth $302,601,000. BlackRock Inc. increased its holdings in shares of Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares during the period. Finally, Ruane Cunniff & Goldfarb L.P. acquired a new position in shares of Zoetis during the first quarter valued at about $286,660,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.8%

NYSE ZTS opened at $75.70 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The stock’s 50 day moving average is $75.53 and its two-hundred day moving average is $93.85. The company has a market capitalization of $31.28 billion, a price-to-earnings ratio of 12.47, a PEG ratio of 1.77 and a beta of 0.73. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $155.15.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s quarterly revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ZTS shares. Morgan Stanley set a $85.00 target price on shares of Zoetis in a research note on Friday, August 7th. Stifel Nicolaus cut their price target on Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a report on Thursday, August 20th. Argus reiterated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Barclays decreased their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Finally, UBS Group lowered their price objective on Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $107.43.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.